{
    "nctId": "NCT05747326",
    "briefTitle": "Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer",
    "officialTitle": "A Doublelet Metronomic Chemotherapeutic Regimen With Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer Patients: A Monocentric Retrospective Study in China",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Progression-free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female;\n* aged \u2265 18 years and \u226475 years;\n* histologically proved metastatic HER-2 negative breast cancer. HER2-negative status determined by situ hybridization (FISH) or immunohistochemistry (IHC) (IHC 0, 1+, 2+ and/or FISH HER2 negative);\n* at least one measurable or evaluable lesion based on RECIST 1.1 criteria;\n* estimated life expectancy \u2265 3 months;\n* normal heart, liver, and kidney function;\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;\n* informed consent signed by the participants\n\nExclusion Criteria:\n\n* received neoadjuvant or adjuvant therapy containing vinorelbine or capecitabine within one year prior to treatment initiation;\n* participated in other new drug clinical trials within 4 weeks before enrollment;\n* inflammatory breast cancer;\n* symptomatic visceral disease;\n* second primary malignancy;\n* mental disorder.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}